Share
Share
Please join us Friday, June 9, from 8:00–11:00 am for the latest from the international DOPPS Program, including our studies of in-center hemodialysis (DOPPS), peritoneal dialysis (PDOPPS), and non-dialysis advanced chronic kidney disease (CKDopps). During the program, we will present what is upcoming in the DOPPS program, and much more:
- Red blood cell transfusions across the DOPPS program
- CKDOPPS takes a deep dive into the transition to dialysis period
- Hemoglobin trajectories and outcomes in patients with CKD
- Recent changes in dialysis CKD-MBD practice patterns
- Recent PDOPPS findings in peritonitis
Session Topics
DOPPS (In-Center Hemodialysis) – 8:20 AM
Impact of etelcalcetide discontinuation on PTH levels in US hemodialysis patients (Junhui Zhao – Arbor Research)
Red blood cell transfusion rates in ND-CKD, HD, and PD (Angelo Karaboyas – Arbor Research)
Platelet count has a U-shaped association with mortality in hemodialysis patients (Xinju Zhao – Beijing, China)
PDOPPS (Peritoneal Dialysis) – 9:05 AM
Gastric acid suppression therapy and its association with peritonitis (Shira Goldman – Tel Aviv, Israel)
Burden and outcomes of pruritus in PD (Karthik Tennankore – Halifax, Canada)
International variations in serum PTH and calcium levels and their mortality associations in PD (Brian Bieber – Arbor Research)
CKDopps (Advanced CKD) – 9:50AM
Hemoglobin trajectories in nondialysis-dependent Chronic Kidney Disease and associated risk of Major Adverse Cardiovascular Events (Lisa Le Gall – Bordeaux, France)
International Variations in Vascular Access Creation and Clinical Outcomes (Murilo Guedes – Arbor Research)
Associations between functionality and clinical outcomes in ND-CKD patients (Antonio Lopes – Salvador, Brazil)
Full agenda is outlined here and in the attached PDF.
See you, Friday, June 9, from 8:00–11:00 am!
Please register before the meeting date.
If you have any questions, please contact us at the DOPPS Program Coordinating Center (DCC) at DOPPS@ArborResearch.org
Individuals with BSEP deficiency with one p.E297G or p.D482G mutation and one PPTM have a similarly severe disease course and low responsiveness to siEHC as those with two PPTMs.
The new office is located in the Metro DC area near clients and partners, offering convenience for meetings and collaboration.
Dr. Stanik to assist Arbor Research with further expansion into long-term care, behavioral health, and mixed methods research
Using a mouse model of BA and human liver gene expression data collected by ChiLDReN, we were able to confirm the likely activation of this pathway known as TWEAK/FN14 in association with liver fibrosis. We further showed that inhibition of this pathway pharmacologically was associated with near complete elimination of fibrosis in the mouse model of BA.
